Phase II data showing an 11.1-month improvement in overall survival for advanced ovarian cancer patients treated with the IL-12 immunotherapy IMNN-001 drove up shares of Imunon Inc. by 181% July 30. The results “could usher in the first immune-based therapy for ovarian cancer,” said Stacy Lindborg, president and CEO of the Lawrenceville, N.J.-based company.
The first patenting to be published in the name of Wave View Imaging Inc. sees its co-founders file for additional protection of their imaging technology which can be used to monitor breast cancer treatment.
Swiss scientists developed hydrogel implants that could help prevent and treat endometriosis by blocking the fallopian tubes and stopping the passage of endometrial cells. The implants, though in their early stage of development, bode well for the millions of women suffering from the chronic condition.
Researchers from Chongqing Medical University and affiliated organizations reported findings from studies they performed to assess the role of zinc-finger protein 334 (ZNF334) in cervical cancer.
Novocuff Inc. closed an oversubscribed $26 million series A funding round to support further development of the Novocuff cervical control system, which is designed to reduce preterm births by closing the cervix in high-risk pregnancies. The funds will enable the company to undertake a U.S. multi-center pivotal clinical trial, pursue marketing authorization, expand its team and begin early-stage commercialization of the device.
Researchers from the University of California San Francisco (UCSF) have found that CCN3, a hormone secreted by neurons in the brain, is responsible for maintaining bone strength during lactation.
A team at Massachusetts General Hospital conducted research to evaluate the expression levels of the extracellular matrix protein tubulointerstitial nephritis antigen-like 1 (TINAGL1) in the human ovary.
Epithelial ovarian cancer (EOC) is the most predominant histologic type of ovarian cancer, with about 55% of patients at an advanced stage when diagnosed; overall survival remains poor.
Clarius Mobile Health Corp. received U.S. FDA clearance for the Clarius OB artificial intelligence biometric measurement tool, which is designed to improve access to accurate prenatal monitoring in low-resource regions. The system automatically estimates fetal age, weight and growth intervals critical to assessing fetal health and early identification of potential issues and multiple pregnancies.
A new non-invasive device which enables women to test themselves at home for signs of the cancer-causing human papillomavirus strains in menstrual blood, has been developed with support from the Venture Builder Incubator at the University of Edinburgh.